熱門資訊> 正文
Kymera Therapeutics宣布拟议承销发行
2024-08-20 04:10
- Kymera Therapeutics (NASDAQ:KYMR) commenced an underwritten public offering of $200M of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
- Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $30M of shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
- Source: Press Release
More on Kymera Therapeutics
- Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript
- Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating
- Kymera Therapeutics GAAP EPS of -$0.58 beats by $0.12, revenue of $25.7M beats by $13.15M
- Biggest stock movers today: BP, INTC, HELE, and more
- Seeking Alpha’s Quant Rating on Kymera Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。